 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- || M1069 / EMD Serono, Domain Therap
Enrollment closed, Metastases: MS201929_0032: First in Human Study of M1069 in Advanced Solid Tumors (clinicaltrials.gov) - Mar 22, 2023
P1, N=30, Active, not recruiting, Sponsor: EMD Serono Research & Development Institute, Inc.
Recruiting --> Active, not recruiting
- || M1069 / EMD Serono, Domain Therap
Enrollment open, Metastases: MS201929_0032: First in Human Study of M1069 in Advanced Solid Tumors (clinicaltrials.gov) - Apr 1, 2022
P1, N=24, Recruiting, Sponsor: EMD Serono Research & Development Institute, Inc.
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- M1069 / EMD Serono, Domain Therap
A first-in-human study of the dual A2A/A2B adenosine receptor antagonist M1069 in patients with advanced solid tumors (Section 35) - Mar 9, 2022 - Abstract #AACR2022AACR_5887;
P1
The target dose-limiting toxicity probability for the MTD is 30% which will be estimated by the BLRM. Pharmacokinetic parameters will be calculated using noncompartmental analysis.The study is open and patients are being treated at the first dose level.
- M1069 / EMD Serono, Domain Therap
M1069 as dual A2A/ A2B adenosine receptor antagonist counteracts immune-suppressive mechanisms of adenosine and reduces tumor growth in vivo (Section 37) - Mar 9, 2022 - Abstract #AACR2022AACR_5472;
These findings were further corroborated with the results from in vivo studies in a murine CD73hi/adenosine-rich 4T1 syngeneic breast tumor model, in which M1069, but not an A2A-selective antagonist, reduced tumor growth as a monotherapy and enhanced anti-tumor activity with chemotherapeutic agents. In summary, M1069 is a potent, dual A2A/A2B adenosine receptor antagonist, which is expected to counteract immune-suppressive mechanisms in the presence of high concentrations of adenosine and enhance the anti-tumor activity of chemotherapies.
- || M1069 / EMD Serono, Domain Therap
New P1 trial, Metastases: MS201929_0032: First in Human Study of M1069 in Advanced Solid Tumors (clinicaltrials.gov) - Jan 20, 2022
P1, N=24, Not yet recruiting, Sponsor: EMD Serono Research & Development Institute, Inc.